Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Du 125530. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 15/20 | 0.68 |
| ▸ | DRD2 | P14416 | 17/20 | 0.65 |
| ▸ | HTR2A | P28223 | 14/20 | 0.65 |
| ▸ | HTR7 | P34969 | 14/20 | 0.65 |
| ▸ | HTR6 | P50406 | 14/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | DRD5 | P21918 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Du 125530 SCHEMBL1082516 | 1.00 | HTR1A (0.68) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Du 125530 SCHEMBL6063602 | 0.99 | HTR1A (0.67) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7820656 | 0.99 | HTR1A (0.67) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7821691 | 0.94 | HTR1A (0.76) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Hydrochloric Acid SCHEMBL9268325 | 0.94 | HTR1A (0.75) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7820777 | 0.91 | HTR1A (0.55) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7833008 | 0.89 | HTR1A (0.68) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7815669 | 0.89 | HTR1A (0.68) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7814640 | 0.87 | HTR1A (0.65) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL7817326 | 0.87 | HTR1A (0.65) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | ATLAS PHARMACEUTICALS BV (BE) | 2022-08-25 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4003347-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | Atlas Pharmaceuticals BV (BE) | 2022-06-01 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-114144179-A | Serotonin-containing agents and 5-HT1A receptor antagonists | 阿特拉斯制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | HTR5A, HTR1A, HTR4 | HTR1A 2/4885DRD2 32/4885HTR2A 4/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | HTR1A 3268/4885DRD2 4158/4885HTR2A 2768/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR1A 1097/4885DRD2 985/4885HTR2A 765/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | HTR1A 1097/4885DRD2 985/4885HTR2A 765/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR1A 1668/4885DRD2 1744/4885HTR2A 1279/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | HTR1A 1668/4885DRD2 1744/4885HTR2A 1279/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR1A 1668/4885DRD2 1744/4885HTR2A 1279/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | HTR1A 2839/4885DRD2 778/4885HTR2A 2101/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | HTR1A 3268/4885DRD2 4204/4885HTR2A 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.